Differential Spinal and Supraspinal Activation of Glia in a Rat Model of Morphine Tolerance by Jokinen, Viljami et al.
NEUROSCIENCE
RESEARCH ARTICLEV. Jokinen et al. / Neuroscience 375 (2018) 10–24Differential Spinal and Supraspinal Activation of Glia in a Rat Model
of Morphine Tolerance
Viljami Jokinen, a* Yulia Sidorova, b Hanna Viisanen, a Ilida Suleymanova, b Henna Tiilikainen, a Zhilin Li, c Tuomas O. Lilius, a
Kert Mätlik, d Jenni E. Anttila, e Mikko Airavaara, e Li Tian, c,f Pekka V. Rauhala a and Eija A. Kalso a,g
aDepartment of Pharmacology, Faculty of Medicine, Haartmaninkatu 8 (Biomedicum), 00014 University of Helsinki, Helsinki, Finland
b Laboratory of Molecular Neuroscience, Institute of Biotechnology, Viikinkaari 5d, 00014 University of Helsinki, Helsinki, Finland
cNeuroscience Center, Helsinki Institute of Life Science, Viikinkaari 4, 00014 University of Helsinki, Helsinki, Finland
dProgram in Developmental Biology, Institute of Biotechnology, Viikinkaari 5d, 00014 University of Helsinki, Helsinki, Finland
e Institute of Biotechnology, Viikinkaari 5d, 00014 University of Helsinki, Helsinki, Finland
fPsychiatric Research Center, Beijing Huilongguan Hospital, Peking University, Beijing, China
gDivision of Pain Medicine, Department of Anaesthesiology, Intensive Care and Pain Medicine, Helsinki University Hospital and University
of Helsinki, Haartmaninkatu 2A, P.O. Box 140, 00029 Helsinki, Finland
Abstract—Development of tolerance is a well known pharmacological characteristic of opioids and a major clin-
ical problem. In addition to the known neuronal mechanisms of opioid tolerance, activation of glia has emerged as
a potentially significant new mechanism. We studied activation of microglia and astrocytes in morphine tolerance
and opioid-induced hyperalgesia in rats using immunohistochemistry, flow cytometry and RNA sequencing in
spinal- and supraspinal regions. Chronic morphine treatment that induced tolerance and hyperalgesia also
increased immunoreactivity of spinal microglia in the dorsal and ventral horns. Flow cytometry demonstrated that
morphine treatment increased the proportion of M2-polarized spinal microglia, but failed to impact the number or
the proportion of M1-polarized microglia. In the transcriptome of microglial cells isolated from the spinal cord
(SC), morphine treatment increased transcripts related to cell activation and defense response. In the studied
brain regions, no activation of microglia or astrocytes was detected by immunohistochemistry, except for a
decrease in the number of microglial cells in the substantia nigra. In flow cytometry, morphine caused a decrease
in the number of microglial cells in the medulla, but otherwise no change was detected for the count or the
proportion of M1- and M2-polarized microglia in the medulla or sensory cortex. No evidence for the activation
of glia in the brain was seen. Our results suggest that glial activation associated with opioid tolerance
and opioid-induced hyperalgesia occurs mainly at the spinal level. The transcriptome data suggest that
the microglial activation pattern after chronic morphine treatment has similarities with that of neuropathic pain.
 2018 IBRO. Published by Elsevier Ltd. All rights reserved.Key words: flow cytometry, opioid, neuroinflammation, nociception, microglia, transcriptomics.https://doi.org/10.1016/j.neuroscience.2018.01.048
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10INTRODUCTION
Morphine and other strong opioids are widely used to treat
moderate to strong acute and cancer pain (Caraceni
et al., 2012). With long-term use, opioid tolerance and
opioid-induced hyperalgesia (OIH) can become major
problems. OIH is a paradoxical phenomenon, where opi-
oids increase rather than alleviate pain. OIH can lead to
cessation of opioid treatment and its replacement with
other analgesics (Tompkins and Campbell, 2011). In
recent years, the role of glia has become increasingly
interesting as a possible mediator of both opioid-induced
tolerance and hyperalgesia. Glia are non-neuronal cells
that regulate the homeostasis of the nervous system.
Microglia- or astrocyte-mediated neuroinflammation has
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ical pain models such as peripheral nerve injury (Cova
et al., 1988; Raghavendra et al., 2003; Zhuang et al.,
2006), spinal cord (SC) injury (Hains and Waxman,
2006), post-operative pain (Obata et al., 2006), and bone
cancer (Zhang et al., 2005). Functional imaging tech-
niques have also provided evidence for glial activation in
the brain of chronic pain patients (Loggia et al., 2015).
Opioids have also been suggested to induce neuroinflam-
mation via glial cells in the SC (Raghavendra et al., 2002;
Watkins et al., 2005; Holdridge et al., 2007; Mattioli et al.,
2010). The implications of opioid-induced glial activation
are not fully understood. However, opioid-induced neu-
roinflammation has been proposed to contribute to mor-
phine tolerance and OIH, as blockade of glial reactivity
or their pro-inflammatory products has been shown to
attenuate both conditions (Grace et al., 2015).
The extent to which opioids activate glial cells and
cause neuroinflammation has been only partially
studied. The effects of opioids on glial activation have
previously been studied mainly in the SC and in some
individual brain regions by using immunohistochemistry.
Recent data have suggested that nociceptors and spinal
structures alone could explain opioid tolerance and OIH
(Corder et al., 2017). Therefore, we assessed glial activa-
tion, not only in the spinal, but also in supraspinal regions
relevant to pain processing in a rat model of morphine tol-
erance and hyperalgesia. In addition to using immunohis-
tochemistry, we used flow cytometry and RNA
sequencing to clarify the cellular and molecular changes.
EXPERIMENTAL PROCEDURES
Animals
Research was conducted in accordance with the
guidelines of the local authorities, International
Association for the Study of Pain (Zimmermann, 1983),
and European Communities Council Directive of 24
November 1986. The provincial government of Southern
Finland (Uudenmaan Lääninhallitus, Hämeenlinna, Fin-
land) had approved the study protocol. Male Sprague-
Dawley rats (Scanbur, Sollentuna, Sweden) weighing
200–250 g at the beginning of experiments were used.
The rats were accommodated in transparent cages, in
groups of four, in temperature-controlled rooms with regu-
lar diurnal light cycle. Water and standard laboratory chow
were available ad libitum. The rats were habituated to the
testing conditions during three days prior to experiments.
Drugs
Morphine hydrochloride was purchased from the
University Pharmacy (Helsinki, Finland). Morphine was
dissolved to 0.9% sodium chloride (saline). Morphine and
its control (saline) were administered subcutaneously (s.
c.) in a volume of 2 mL/kg. The morphine doses are given
as free base amounts per unit of volume.
Behavioral tests
All behavioral measurements were performed in a
randomized and blinded fashion. Tail flick latencies weretested with an Ugo Basile 37360 tail flick apparatus
(Comerio, Italy). The rats were restrained in plastic
tubes, the tail coming out of the tube. At each time
point, three different points of the middle third of the tail
were subjected to the light of the apparatus. The
intensity of the light was adjusted to produce a baseline
latency of 3.2 ± 0.6 s (n = 30). Flick of the tail
terminated the infrared light and stopped the timer of
the apparatus. The mean of the results was then
calculated. To avoid tissue damage, the cut-off was set
to 10 s. If a measurement reached the cut-off, no further
tests were performed for that time point.
Mechanical thresholds were assessed using the Ugo
Basile 37450 Dynamic Plantar Aesthesiometer (DPA),
(Comerio, Italy). The rats were placed on a metal mesh
in cubic plastic cages and habituated 10 min before
testing. A dull monofilament with a diameter of 0.5 mm
was applied perpendicularly to the middle of the
hindpaw of the rat. The pressure was gradually
increased until a rapid withdrawal or shaking of the paw
occurred. The filament withdrew automatically after the
reaction and the apparatus stored the threshold of the
force needed to cause the reaction. Both hindpaws of
each rat were tested consecutively with an interval of 1
min and the mean of the measurements was calculated.
A 40-g cut-off was used.
Cold thresholds were measured with the Bioseb T2CT
Cold/Hot plate apparatus (Vitrolles, France) as adapted
from Allchorne et al. (2005). The temperature of the plate
was set to 0 C which the apparatus kept constant during
the measurements. The rat was set free onto the appara-
tus plate in a transparent cylinder. The time to the first lift
or stomp of the hindpaw was recorded. Lift of the paw that
was involved in coordinated movement of all four limbs
was excluded. A cut-off of 180 s was used.Experimental design
The rats were administered morphine 10 mg/kg or saline
twice daily for 14 days. The first injection of the day was
given at 10 a.m. (morning injection) and the second at 7
p.m. (evening injection). The behavioral measurements
were performed on experiment days 1, 3, 7, 10, and 13
(tail flick and DPA) and 3, 8, and 14 (cold plate). The
tail flick, DPA, and cold plate tests were performed
before the morning injection (approximately 12 h from
the evening injection). The tail flick test was performed
also one hour after the morning injection. For
immunohistochemistry, flow cytometry, and
transcriptomics studies, another set of rats with a similar
drug administration scheme and development of
morphine tolerance was used. However, staining of
substance P and calcitonin gene-related peptide
(CGRP) was performed from the first set of animals.Immunohistochemistry
After completion of the behavioral studies, tissues of
animals were collected and fixed with 4% PFA and
embedded to paraffin blocks. Sections of 10 lm
thickness were prepared from lumbar regions of the
SCs (Fig. 1) and selected regions of the brain. The
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located and cropped according to the atlas of Paxinos
and Watson (1998). Sections were probed with antibodies
for Ionized calcium-binding adapter molecule 1 (Iba1)
(1:1000, Cat. No. 019-19741, Wako, Richmond, VA,
USA), GFAP (1:400, Cat. No. G-3893, Sigma–Aldrich,
St. Louis, MO, USA), CGRP (1:10,000, Cat. No. T-
4032, Peninsula Laboratories, San Carlos, CA, USA) or
substance P (1:10,000, Cat. No. T-4107, Peninsula Labo-
ratories). Bound antibodies were visualized using anti-
rabbit and anti-mouse biotinylated secondary antibodies
and the VECTASTAIN ABC HRP Kit (Cat. No. PK-6101,
PK-4002 Vector Laboratories, Burlingame, CA, USA) as
described by the manufacturer. Slides were imaged using
the 3DHISTECH Scanner (3DHISTECH Ltd, Budapest,
Hungary) and scanning service provided by http://www.
biocenter.helsinki.fi/bi/histoscanner/index.html). Images
were analyzed with Matlab R2014b software (Mathworks,
Natick, MA, USA). The number of Iba1 or GFAP-positive
cells was quantified using manually-set size and intensity
thresholds as described previously (Penttinen et al.,
2016). The number of cells was normalized to the area
of analyzed tissue. Since the morphology of glial cells is
changed upon activation, we also analyzed the area cov-
ered by immunopositive stainings, determined as the total
number of pixels with intensity above the selected thresh-
old and normalized to the area of analyzed tissue in pix-
els. For each animal and studied region, 2–4 non-
consecutive sections were analyzed and results were
averaged.Flow cytometry
Rats were deeply anaesthetized with isoflurane and
perfused intracardially with 100 ml phosphate buffered
saline (PBS). The L4–L6 segments of the lumbar SC,
medulla and primary somatosensory cortex (PSC) were
then dissected. Dissected tissues were weighed, cut
into tiny pieces, and gently homogenized through 70 mm
cell strainers (Fisher Scientific, Waltham, MA, USA) in
PBS/1% FBS. Single cell suspensions prepared from
25 mg tissue per sample were blocked with 5% normal
rat serum, and stained with a combination of anti-rat
flow cytometric markers, including Granulocyte-FITCFig. 1. Depiction of the definition of the dorsal and ventral horn of the sp
immunohistochemistry. The scale bar = 500 mm.(clone HIS48, eBioscience, San Diego, CA, USA),
CD172a-PE (clone OX41, BioLegend, San Diego CA,
USA), MHCII-PerCP-eFluor 710 (clone OX17,
eBioscience), and CD11b/c-eFluor 660 (clone OX42,
eBioscience) with light protection at 4 C for 60-min with
continuous rotation. After washing, cells were
resuspended into 2 ml PBS/1% FBS/0.02% NaN3 buffer,
and acquired on a 2-laser, 6-color Gallios cytometer
(Beckman Coulter, Brea, CA, USA) under a live gate of
CD11b/c+. Flow cytometric data were analyzed with the
Kaluza flow analysis 1.3 software (Beckman Coulter).
Microglia were defined as CD11b/c+ Granulocyte total,
MHCII+ and CD172a+ subtypes. However, some
macrophages might be included in the CD11b/c+
Granulocyte cells. Cell populations were calculated
and presented as numbers of cells per mg tissue-
weight, percentages among total microglia, or MHCII+/
CD172a+ microglial ratios.
Microglia RNA isolation (CD11b positive cells)
Rats were perfused transcardially with 200 ml of 0.9%
saline solution and a L1–L6 segment of the SC was
collected for the isolation of CD11b immunopositive
microglia/macrophages by magnetic-activated cell
sorting (MACS). The tissue was dissociated using
Neural tissue dissociation kit (T) (Miltenyi Biotec, San
Diego, CA, USA; cat# 130-093-231) and the
gentleMACS Dissociator (Miltenyi Biotec). After
dissociation, the cells were suspended in 0.5% bovine
serum albumin (BSA) in PBS and incubated with Myelin
Removal Beads II (Miltenyi Biotec; cat# 130-096-733;
1:10 dilution) for 15 min at 4 C. The cells were washed
once and resuspended in 0.5% BSA in PBS and filtered
through an LS column (Miltenyi Biotec; cat# 130-042-
401) using a QuadroMACS Separator (Miltenyi Biotec).
The total effluent was collected and resuspended in
0.5% BSA with 2 mM EDTA in PBS (washing buffer).
The cells were incubated with mouse anti-CD11b:FITC
antibody (AbD Serotec, Puchheim, Germany; Cat#
MCA275FB; 1:10 dilution) at 4 C for 10 min. The cells
were washed once, resuspended in the washing buffer
and incubated with anti-FITC MicroBeads (Miltenyi
Biotec; cat# 130-048-701; 1:10 dilution) for 15 min at 4inal cord used inC. The cells were washed once and
resuspended in the washing buffer.
The cell suspension was applied to
an LS column placed on a
QuadroMACS Separator and the
anti-CD11b-labeled cells were
collected from the column for further
experiments. RNA was extracted
with Trizol reagent, alcohol-
precipitated in the presence of
glycogen and treated with DNase
(#1906, Ambion).
In order to validate the purity of
the isolate, we looked for known
microglial markers, Cx3cr1, P2ry12,
Ctss, Csf1r, and Cst3 (Denk et al.,
2016; Butovsky et al., 2014). All the
markers were expressed in the top
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data (data not shown).RNA sequencing
Altogether 30 ng of total RNA was first submitted to rRNA
and mitochondrial rRNA removal, using RiboGone –
Mammalian–kit (Clonetech, Mountain View, CA, USA),
and then used as a starting material for RNA-Seq.
SMARTer Stranded RNA-Seq Kit (Clonetech,
Mountain View, CA, USA) was used to generate
indexed cDNA libraries from 200 pg of the ribosomal/
mitochondrial RNA-depleted RNA. Strand-specific
sequencing data from the synthesized cDNA was
obtained from the Illumina next generation sequencing
system: the NextSeq High SE 1  75 bp run was used.
Initial quality control on sequenced reads was
performed with FastQC v0.11.3. Based on the quality
reports produced, Illumina adapters were removed by
Trimmomatic v0.33 and the read files were
preprocessed with the following settings: Reads with the
first five bases were trimmed from the start of the read.
Base quality scores less than 30 were trimmed from the
50 end. Reads of length less than 20 bases were
discarded. Had the samples had less than 70% of reads
surviving trimming, they would have been discarded
from further analysis.
The processed reads were then mapped to the
reference genome (Rat Ensembl5) with Tophat v2.1.0
allowing for up to two mismatches (both in the initial
read and the segmented read alignment) and enforcing
rules for first-strand synthesis library type. The mapped
reads were then quantified in fragments per kilobase of
mapped reads (FPKM) with Cufflinks v2.2.1 using
multiple read correction and upper-quartile
normalization. Differential expression analysis was
performed at the gene level using CuffDiff v2.2.1 with
multiple read corrections.
The data (significantly impacted pathways and
biological processes) were further analyzed using
Advaita Bio’s iPathwayGuide (http://www.
advaitabio.com/ipathwayguide).Statistical analysis
In the text and figures, results are presented as mean of
the sample values + standard error of the mean (SEM).
The behavioral data were tested for statistically
significant differences in the mean values by two-way
analysis of variance repeated-measures followed by a
two-tailed Holm–Sidak correction for multiple
comparisons. For the cold-plate test results the data
from day 14 were analyzed using unpaired two-tailed T-
test with Welch’s correction. The immunohistochemistry
data (Iba1 and GFAP staining) were tested for
statistically significant differences by two-way analysis of
variance followed by a two-tailed Holm–Sidak correction
for multiple comparisons, except for the CGRP and
substance P staining that were analyzed with unpaired
two-tailed T-test with Welch’s correction. Fluorescence-
activated cell sorting (FACS) data were tested for
statistically significant differences with unpaired two-tailed T-test with Welch’s correction. Differentially
expressed (DE) genes were defined to have a q-value
(False Discovery Rate adjusted p-value) < 0.05. In the
iPathway analysis, the differential expression threshold
for the gene fold change was set to 0.5 (log2) and q-
value 0.05. False discovery rate p-value correction was
applied for GO-enrichment analysis and impacted
phenotype analysis. The difference was considered
significant at p < 0.05.RESULTS
Antinociceptive tolerance and hyperalgesia following
repeated morphine administration
Behavioral signs of morphine antinociceptive tolerance
and hyperalgesia were seen in the rats during the
experimental period of 13 days. On day 1, morphine 10
mg/kg s.c. caused a cut-off latency of 10 s in the tail
flick test 1 h after administration, whereas the mean
latency in the saline-treated rats was 3.2 s (p< 0.01,
Fig. 2A). In similar measurements on days 3 and 7, the
mean tail flick latencies after morphine 10 mg/kg
gradually decreased to 8.2 and 6.7 s, respectively
(Fig. 2A). Complete tolerance to the antinociceptive
effect of morphine had developed by day 10 (Fig. 2A).
Chronic morphine treatment failed to significantly
change the baseline values in the tail flick test on days
3, 7, 10, and 13 (12 h from the last morphine injection)
compared with the saline group (Fig. 2A).
The Dynamic Plantar Aesthesiometer test (DPA) was
measured on days 1, 3, 7, 10, and 13 (12 h from the last
morphine injection on days 3, 7, 10, and 13). The
threshold observed for morphine-treated rats was
decreased compared with saline-treated rats on day 10
(p < 0.05, Fig. 2B). On days 1, 3, 7, and 13, there were
no significant differences between the groups (Fig. 2B).
The cold plate test was performed on days 8, 12, and
14 (12 h from the last morphine injection). The nociceptive
latency of the morphine-treated rats was significantly
decreased compared with the saline group on days 8
and 12 (Fig. 2C). Despite the trend, the difference
between the treatment and control groups failed to
reach significance on day 14 (Fig. 2C).Morphine increases immunoreactivity of microglial
marker Iba1, substance P, and CGRP in SC
To determine whether chronic morphine treatment leads
to an increase in the number or area of glial cells in the
SC and brain, we analyzed the cells expressing Iba1
and GFAP, commonly used markers of microglia and
astrocytes, respectively.
SC IBA1: Representative samples of dorsal and
ventral horn Iba1 staining of both treatment groups are
shown in Fig. 3A. Compared with saline-treated
animals, the number of cells was increased in the dorsal
horn in the morphine group by 33% (p< 0.01, Fig. 3B).
The area of positive staining per area of tissue was
increased in the dorsal horn in the morphine group
compared with the saline group by 32% (p< 0.01,
Fig. 2. Antinociceptive tolerance and hyperalgesia following repeated morphine administration. The effect of morphine in the tail flick (A), dynamic
plantar aesthesiometer (B), and cold plate (C) tests. The rats were administered morphine 10 mg/kg, s.c. or saline twice daily for 14 days. The
baseline values (12 h after the last morphine injection, except on day 1) were measured with all nociceptive tests. The tail flick test was also
performed one hour after the morphine injection on every measurement day. Statistically significant difference *p< 0.05, **p < 0.01 as compared
with saline control. n = 14–15 rats per group, except for the cold plate test on day 14, where n= 10–11 rats per group.
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Fig. 3C).
SC GFAP: Representative samples of dorsal and
ventral horn GFAP stainings of saline and morphine
treatment groups are shown in Fig. 4A. Compared with
the saline group, chronic morphine administration failed
to change the number of cells expressing GFAP
(Fig. 4B) or the area of positive staining per area
(Fig. 4C) in the dorsal or ventral horns.
To determine whether chronic morphine treatment
leads to an increase in the neuropeptides that are
reported to activate glia, we analyzed the area covered
by CGRP and substance P positive immunoreactivity in
dorsal horn of the SC.SC CGRP and substance P. The area covered by
substance P-positive staining was increased in the
dorsal horn in the morphine group compared with the
saline group by 109% (p< 0.05, Fig. 5A) and CGRP-
positive staining by 106% (p< 0.01, Fig. 5B).
Representative photomicrographs of substance P- and
CGRP-positive stainings are shown in Fig. 5C, D.Morphine fails to increase Iba1 and GFAP
immunoreactivity in the brain areas relevant for pain
processingBrain IBA1. Compared with the saline group, the
number of cells was decreased in the substantia nigra in
the morphine group by 39% (p< 0.05, Fig. 6A). In the
striatum, forelimb area of cortex, nucleus accumbens,
ventral posterolateral nucleus, medial dorsal nucleus,
central amygdala, ventral tegmental area, central gray,
and rostroventral medulla, the number of cells were not
significantly changed (Fig. 6A). The areas of positive
staining per areas of tissue were not significantly
changed between the morphine and saline groups in
any of the studied brain areas (Fig. 6C).Brain GFAP. The number of cells or the area of
positive staining per area of tissue was statistically
unchanged in the studied brain regions (Fig. 6B, D).In flow cytometry, the total amount of microglia
decreases in the medulla and the proportion of
M2-polarized microglia increases in the SC after
morphine treatment
Next we used flow cytometry to complement the
immunohistochemistry analysis. In flow cytometry, the
total amount of microglia was decreased by 13% (p<
0.05) in the morphine-treated group compared with the
saline group in the medulla (Fig. 7A). In the sensory
cortex and SC, the amount of microglia was not
significantly changed between the morphine and saline
groups (Fig. 7B, C). Compared with the saline group,
morphine treatment increased the proportion (%) of M2-
(CD172a+) microglia in total microglia in the SC by
70% (p< 0.01, Fig. 7C), but not in the medulla and
sensory cortex. The proportion of M1-microglia of the
total microglia was not otherwise significantly changed
between the morphine and saline groups in the medulla,
sensory cortex, or SC. Examples and gating strategy for
total microglia, M1-, and M2-microglia in saline and
morphine treatment are shown in the SC in Fig. 7D.Repeated morphine administration changes RNA
transcriptomics in spinal microglia – expression of
the DAP12 pathway genes is significantly
upregulated
The transcriptomics was performed on microglia cells
(CD11b+) isolated from the SCs of three rats from both
morphine and saline-treatment groups to assess the
morphine-induced transcriptional changes in microglia.
The differential expression (DE) analysis detected 2454
differentially expressed genes between the treatment
groups.
In the gene ontology (GO) enrichment analysis, the
following GO terms were significantly enriched: immune
system process, responses to stress, catabolic process,
defense response, organic substance catabolic process,
cell activation, and cellular catabolic process. In the
impacted phenotype pathway analysis, the genes
related to the phagosome route were significantly over-
represented. Expression of the genes of the DAP12
pathway (Kobayashi et al., 2016), Trem2, Tyrobp, Irf8,
Fig. 3. Morphine increases Iba1 immunoreactivity in spinal cord. Representative photomicrographs of the saline and morphine treatment groups of
dorsal and ventral horn are shown in the top row (A). The number of cells per area of tissue (B) and area of positive staining per area of tissue (C) in
the dorsal and ventral horn of the spinal cord with Iba1 staining after morphine 10 mg/kg, s.c. or saline twice a day for 14 days. Statistically
significant difference *p< 0.05, **p < 0.01 as compared with the saline control. n = 5 in both groups. The scale bar = 500 mm.
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Other DAP12 pathway related genes (Cx3cr1, Ctss, and
Csf1r) were also upregulated, but the change was statis-
tically non-significant (Table 1). In addition, other individ-
ual genes were significantly upregulated, including:
Kcnn4, Fkbp5, Fcgr1a, and Cd244 (Table 1).DISCUSSION
We found that chronic morphine treatment induced
tolerance and hyperalgesia in the rat. The treatment
also increased the number of microglial cells in thedorsal and ventral horns of the SC and immunoreactivity
of substance P and CGRP in the dorsal horn. However,
neither the number nor the area of astrocytes in the SC
was changed. In flow cytometry, morphine treatment
increased the proportion of M2-polarized microglia in the
SC but did not change either the number or the
proportion of M1-polarized microglia. In the
transcriptome of the microglial cells isolated from the
SC, morphine treatment increased the transcripts
related to cell activation and defense response.
Interestingly, in this study, glial reactivity increased only
at the spinal but not supraspinal level. In the studied
Fig. 4. Morphine does not increase GFAP immunoreactivity in spinal cord. Representative photomicrographs of dorsal and ventral horn GFAP
stainings of both treatment groups (A). The Number of cells per area of tissue (B) or area of positive staining per area of tissue (C) in the dorsal and
ventral horn of spinal cord with GFAP staining after morphine 10 mg/kg, s.c. or saline injections twice daily for 14 days. n = 5 in both groups. The
scale bar = 500 mm.
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in the number or area of microglia or astrocytes, except
for a decrease in the number of microglial cells in the
substantia nigra. In flow cytometry, morphine treatment
reduced the number of microglial cells in the medulla
with no change in the proportion of M1- and M2-
polarized microglia.
In this study, the rats became tolerant to the
antinociceptive effect of morphine after a ten-day
morphine treatment. Signs of opioid-induced
hyperalgesia were detected in both mechanical and coldnociceptive tests 12 h after morphine injection.
Concurrently, the treatment increased the number of
microglial cells by 33% in the dorsal horn of the SC
when the classical microglia marker Iba1 was used. In
the ventral horn, the area of microglial cells increased
by 24%, which we consider to be related to the increase
in the cell number, as the number of cells was
increased 22%, although not significantly.
The increase of microglial cells in the dorsal horn is in
agreement with previous studies that have described the
activation of glia after chronic morphine treatment
Fig. 5. Morphine enhances substance P and calcitonin gene-related peptide immunoreactivity in spinal cord. Area covered by substance P (A) and
CGRP (B) -positive staining in the dorsal horn of the spinal cord after morphine 10 mg/kg, s.c. or saline twice daily for 14 days. Representative
photomicrogprahs of substance P (C) and CGRP (D) -positive staining in both treatment groups. Statistically significant *p < 0.05, **p< 0.01 as
compared with the saline control. n = 4–5 in both groups. The scale bar = 500 mm.
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et al., 2008; Mattioli et al., 2010; Wang et al., 2010).
The magnitude of the change in microglial immunoreactiv-
ity is also in the same range as previously reported by
Holdridge et al. (60%) after systemic administration of
morphine. Larger increases have been detected (300%)
after subarachnoid administration of morphine (Cui
et al., 2008).
Both proliferation and hypertrophy of microglia have
been described as a response to insult (Gwak et al.,
2012) and they both are considered to reflect activation
of glia (Ji et al., 2013). In agreement with the studies of
Jun et al (Jun et al., 2013) and Wang et al (Wang et al.,
2010) our results suggest that the opioid-induced spinal
microglia activation might not be restricted to hypertrophy
and could resemble that of the peripheral nerve injury
where microglia proliferation (Melzer et al., 1997;
Echeverry et al., 2008) has been detected.
Interestingly, systemic administration of high doses of
morphine also increased the number of microglial cells in
the ventral horn. Cui et al. have also shown that
subarachnoid administration of chronic morphine causes
activation of microglia but not astrocytes in the ventral
horn (Cui et al., 2006). There is some evidence to suggest
that opioid-induced neuroinflammation in the ventral horn
could have pathological consequences. High doses of
subarachnoid morphine (40 lg  2 daily) have been
reported to induce paraplegia with degeneration of spinal
ventral neurons (Kakinohana et al., 2007).Our understanding of how morphine activates glia
remains incomplete. Recent reports suggest that no l-
opioid receptors are expressed in the microglia or
astrocytes in the SC of naı̈ve or morphine-treated
animals (Kao et al., 2012; Corder et al., 2017). Toll-
Like Receptor 4 (TLR-4) has been suggested to be a
key mediator in opioid-induced activation or microglia
(Watkins et al., 2009). Its role in morphine-induced tol-
erance and hyperalgesia, however, has also been ques-
tioned, as neither were altered in TLR4 null mice
(Mattioli et al., 2014). In our study, chronic morphine
treatment increased the neuron-derived peptides sub-
stance P and CGRP in the dorsal horn, which agrees
with previous reports (Powell et al., 2000; Melik
Parsadaniantz et al., 2015). Both substance P (Zhu
et al., 2014) and CGRP (Reddington et al., 1995) have
been shown to activate glial cells. Thus, it is possible
that morphine effects on glial cells are l-opioid-
receptor independent.
A diverse set of activated microglial phenotypes has
been identified (Luo and Chen, 2012). Thus, the classical
approach that utilizes single histochemical markers might
provide an incomplete picture of the activation asmicroglial
cells, which have different properties with some of them
having pro- and others anti-inflammatory effects. There-
fore, we wanted to investigate the activated microglia in
more detail using flow cytometry. The M1 (pro-
inflammatory) and M2 (anti-inflammatory)-paradigm has
been used to polarize microglial phenotypes according to
Fig. 6. Morphine does not increase Iba1-associated microglia or GFAP immunoreactivity in the brain. Number of cells per area of tissue (A, B) or
area of positive staining per area of tissue (C, D) in the referred brain regions with IBA1 and GFAP-staining after morphine 10 mg/kg, s.c. or saline
twice a day for 14 days. Statistically significant difference **p < 0.01 as compared with the saline group. n = 5 in both groups.
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and Fernandez-Suarez, 2015; Tang and Le, 2016). M1/2
microglia activation was not studied previously in the con-
text of chronic morphine administration. We defined M2
microglia according to highexpressionofCD172a (SIRPa),
which has been shown to prevent phagocytosis and to
exert anti-inflammatory properties when paired with
CD47 (Latour et al., 2001; Barclay and Van den Berg,
2014; Gitik et al., 2014). It should be stated, however, that
the concept of M1 and M2 polarization may over-simplify
the broad spectrum of microglial activation phenotypes,
but also that heterogeneity of microglial populations is not
only limited to M1/2 phenotypes (Cherry et al., 2014;
Chen and Trapp, 2016; Ransohoff, 2016). The activation
of microglia seems to be context-dependent (Cherry
et al., 2014). This would be in harmony with the idea that
microglia need to beable to react to adiverse set of external
challenges. Thus, a limitation of this studywas thatweused
only one marker per cell type, MHCII+ to define M1-
microglia and CD172a+ to define M2-microglia, which
account for only a fraction of the total microglia. Further-
more, it should be mentioned that CD11b/c+ which was
used to define microglia is also associated with
macrophages.
In our investigation, the increased proportion of M2-
microglia in the SC could be interpreted as an effort toresolve the neuroinflammation caused by chronic
morphine administration. Analogously, a rise in the
proportion of similarly defined M2-microglia in the SC has
been detected seven days after peripheral nerve injury in
the rat (Li et al., 2016). In accordance with this hypothesis,
parthenolide, known to affect intracellular microglial inflam-
mation pathways, like p-38 and ERK1/2 (Popiolek-Barczyk
et al., 2015), has promoted spinal M2 microglia/-
macrophage polarization and relieved pain in a rat model
of neuropathy (Popiolek-Barczyk et al., 2015). Considering
the role of activated glia in both neuropathic pain and
opioid-induced neuroinflammation, drugs that promote
M2-conversion of spinal microglia could be beneficial also
in the treatment of OIH and attenuation of morphine
tolerance.
In flow cytometry, the total amount of microglia
(CD11b/c+Granulocyte) and the proportion of the pro-
inflammatory M1-microglia (CD172MHCII+) were
unchanged in the SC after morphine treatment. Flow
cytometry differentiates the cells by the expression
levels of the used antibodies and the microglia
populations defined this way may not necessarily
correspond with those characterized by
immunohistochemistry. Thus, assays using both
immunohistochemistry and flow cytometry might provide
a complementary way to assess microglial activation.
Fig. 7. In flow cytometry, the total amount of microglia decreases in the medulla and the proportion of M2-polarized microglia increases in the spinal
cord after morphine treatment. The number of microglial cells per mg tissue and the proportion of M1 and M2 microglia among total microglia in
medulla (A), sensory cortex (B), and spinal cord (C) after morphine 10 mg/kg, s.c. or saline twice a day for 14 days. Statistically significant difference
*p< 0.05, **p< 0.01 as compared to the saline group. n = 4–5 in both groups. Example of gating strategies of saline- and morphine-treated
samples of the total microglia (CD11b/c+), M1 (MHCII+), and M2 (CD172a+) microglia for the spinal cord (D). MG/M/ =Microglia/macrophage.
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chronic morphine, transcriptome analysis of the isolated
spinal microglia was performed. In the analysis, the
following GO terms were significantly enriched: immune
system process, response to stress catabolic process,
defense response, organic substance catabolic process,
cell activation, and cellular catabolic process. In
addition, the genes in the ‘phagosome’ phenotype
pathway were over-represented. Interestingly, the
phagosome pathway has also been shown previously to
be activated after the administration of bacterial
lipopolysaccharide in mouse microglia and to associateto the loss of dopaminergic neurons (Bodea et al.,
2014). The results would indicate that morphine acts as
a noxious stimulus to microglia.
Many renowned individual genes related to pain and
inflammatory activation were also differentially
expressed. We found that the DAP12 pathway
associated genes (Guan et al., 2016), Tyrobp, Irf8, Irf5,
and P2rx4, were significantly up-regulated. Csf1r, Cx3cr1,
and Ctss were also up-regulated, but the change was
non-significant. The DAP12 pathway, along with its
individual downstream molecules, has been suggested
to be an essential contributor to neuropathic pain
Table 1. Changes of expression levels of individual genes in microglia. Microglial cells were isolated from
the spinal cord after chronic morphine treatment 10 mg/kg, s.c. or saline twice daily for 14 days. The results
are quantified in log2-fold change of morphine vs saline-treatment groups. n = 3 in both groups.
1Fragments Per Kilobase of exon per Million fragments mapped. 2False Discovery Rate adjusted p-value
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included other DE genes that have been highlighted in
neuropathic pain such as Cd244, Fcgr1 (Denk et al.,
2016). Interestingly, we also detected upregulation of
Fkbp5. Silencing of Fkbp51 (same as Fkbp5) in the SC
has led to reduced hypersensitivity in a rodent model of
neuropathic pain (Maiaru et al., 2016) but no study has
yet demonstrated its up-regulation in microglia in associa-
tion with chronic morphine treatment. Kcnn4 has been
shown to promote microglial activation and consequent
neurotoxicity (Kaushal et al., 2007), and it is up-
regulated in M2-microglia where it promotes cell migration
(Ferreira et al., 2014). Activation of TREM2 elicits a pro-
inflammatory response in microglia and exacerbates neu-
ropathic pain in the DAP12/TREM2 pathway (Kobayashi
et al., 2016).
Opioid-induced activation of glia has been less studied
in the supraspinal structures than in the SC. Although the
role of the SC in the transmission and modulation of
nociception is crucial, it constitutes only part of the
structures critical for the processing of nociception and
pain. For example, in humans, nucleus accumbens has
been shown to be involved in the transition to chronic
pain (Baliki et al., 2010) and the amygdala contributes
to the negative affective states related to pain (Veinante
et al., 2013).
In our study, neither the count nor the area of
microglia or astrocytes were significantly changed in the
striatum, forelimb area of cortex, nucleus accumbens,
ventral posterolateral nucleus, medial dorsal nucleus,central amygdala, ventral tegmental area, central grey,
or rostroventral medulla. Previous literature regarding
the activation of supraspinal glia after chronic morphine
is inconsistent. For example, the immunoreactivity of
microglia was increased in nucleus accumbens in the
study of Zhang et al. (2012) but decreased in a study by
Hutchinson et al. (2009). Activation of microglia in the
periaqueductal grey was detected by Hutchinson et al.
(2009) and Eidson and Murphy (2013), but not by Bajic
et al. (2013). Nonetheless, supraspinal activation of astro-
cytes and microglia has been detected in the ventral
tegmental area after opioid administration (Hutchinson
et al., 2009; Garcı́a-Pérez et al., 2016; Taylor et al.,
2016). The discrepancy with our results and others could
be related to the differences in the study settings, like the
morphine tolerance induction scheme and the rat strain.
In our study we looked at both spinal and supraspinal glial
activation and showed activation in the spinal but not in
the supraspinal level. Thus it could be hypothesized that
glial activation in the studied supraspinal structures might
not be necessary for the development of tolerance or
opioid-induced hyperalgesia. This is in agreement with a
recent study suggesting that supraspinal structures are
not required for the development of opioid tolerance and
OIH (Corder et al., 2017).
Some of the findings of this study were surprising,
including the reduced microgliosis in the substantia
nigra and medulla and the increased immunoreactivity
of microglia in the ventral horn. Because the ventral
horn of the SC is part of the pyramidal pathway,
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nigra modulates movement through the extrapyramidal
system, it would be tempting to hypothesize that the
effects of chronic morphine on activation of microglia
would affect motor function. Chronic use of high doses
of opioids is known to occasionally associate with
myoclonus in humans (Bowdle and Rooke, 1994;
Mercadante, 1998). However, the possible effects of
reduced microgliosis in the substantia nigra to the pro-
cessing of nociception and pain cannot be excluded.
Intranigral microinjection of naloxone has suppressed
the antinociceptive effects of systemically administered
morphine in thermal nociceptive tests in a dose-related
manner (Baumeister et al., 1988). Hypersensitivity to nox-
ious stimulation has also been reported to possibly be
involved in unilateral dopamine depletion in the nigrostri-
atal pathway in the rat (Maegawa et al., 2015).
Morphine-induced glia-mediated neuroinflammation is
a complex molecular system and it is probable that
multiple subpopulations of glia are involved in its
initiation and resolution. Identifying the relevant
pathological glial populations as well as the vulnerable
neuroanatomical systems, such as the substantia nigra,
is important in order to understand the possible
neurodegenerative consequences of long-term opioid
administration. It cannot be excluded that Iba1 and
GFAP immunostainings were unable to demonstrate the
relevant populations of glia and in that case other
approaches should be used to study this in more depth.
The use of advanced methods like flow cytometry and
RNA sequencing can provide detailed information of the
glial activation and help to determine more useful
biomarkers, as well as to develop new treatment
methods.CONCLUSION
We presented a comprehensive set of data on glial
activation in the SC and brain. Our results suggest that
microglial activation associated with opioid tolerance
and opioid-induced hyperalgesia occurs mainly at the
spinal level. The transcriptome data suggest that the
pattern of microglial activation after chronic morphine
treatment is similar to that of neuropathic pain.DISCLOSURE STATEMENT
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Garcı́a-Pérez D, Laorden ML, Milanés MV (2016) Regulation of
pleiotrophin, midkine, receptor protein tyrosine phosphatase b/f,
and their intracellular signaling cascades in the nucleus
accumbens during opiate administration. Int J
Neuropsychopharmacol:19.
Gitik M, Kleinhaus R, Hadas S, Reichert F, Rotshenker S (2014)
Phagocytic receptors activate and immune inhibitory receptor
SIRPa inhibits phagocytosis through paxillin and cofilin. Front Cell
Neurosci:8.
Grace PM, Maier SF, Watkins LR (2015) Opioid-induced central
immune signaling: implications for opioid analgesia. Headache
55:475–489.
Guan Z, Kuhn JA, Wang X, Colquitt B, Solorzano C, Vaman S, Guan
AK, Evans-Reinsch Z, Braz J, Devor M, Abboud-Werner SL,
Lanier LL, Lomvardas S, Basbaum AI (2016) Injured sensory
neuron-derived CSF1 induces microglial proliferation and DAP12-
dependent pain. Nat Neurosci 19:94–101.
Gwak YS, Kang J, Unabia GC, Hulsebosch CE (2012) Spatial and
temporal activation of spinal glial cells: role of gliopathy in central
neuropathic pain following spinal cord injury in rats. Exp Neurol
234:362–372.
Hains BC, Waxman SG (2006) Activated microglia contribute to the
maintenance of chronic pain after spinal cord injury. J Neurosci
26:4308–4317.
Holdridge SV, Armstrong SA, Taylor AMW, Cahill CM (2007)
Behavioural and morphological evidence for the involvement of
glial cell activation in delta opioid receptor function: implications
for the development of opioid tolerance. Mol Pain 3:7.
Hutchinson MR, Lewis SS, Coats BD, Skyba DA, Crysdale NY,
Berkelhammer DL, Brzeski A, Northcutt A, Vietz CM, Judd CM,
Maier SF, Watkins LR, Johnson KW (2009) Reduction of opioid
withdrawal and potentiation of acute opioid analgesia by systemic
AV411 (ibudilast). Brain Behav Immun 23:240–250.
Ji R-R, Berta T, Nedergaard M (2013) Glia and pain: is chronic pain a
gliopathy? Pain 154(Suppl. 1):S10–S28.
Jun I-G, Kim S-H, Yoon Y-I, Park J-Y (2013) Intrathecal lamotrigine
attenuates antinociceptive morphine tolerance and suppresses
spinal glial cell activation in morphine-tolerant rats. J Kor Med Sci
28:300–307.
Kakinohana M, Oshiro M, Saikawa S, Nakamura S, Higa T, Davison
KJ, Marsala M, Sugahara K (2007) Intravenous infusion of
dexmedetomidine can prevent the degeneration of spinal ventral
neurons induced by intrathecal morphine after a noninjurious
interval of spinal cord ischemia in rats. Anesth Analg
105:1086–1093.
Kao S-C, Zhao X, Lee C-Y, Atianjoh FE, Gauda EB, Yaster M, Tao Y-
X (2012) Absence of mu opioid receptor mRNA expression inastrocytes and microglia of rat spinal cord. NeuroReport
23:378–384.
Kaushal V, Koeberle PD, Wang Y, Schlichter LC (2007) The Ca2+-
activated K+ channel KCNN4/KCa3.1 contributes to microglia
activation and nitric oxide-dependent neurodegeneration. J
Neurosci 27:234–244.
Kobayashi M, Konishi H, Sayo A, Takai T, Kiyama H (2016) TREM2/
DAP12 signal elicits proinflammatory response in microglia and
exacerbates neuropathic pain. J Neurosci 36:11138–11150.
Latour S, Tanaka H, Demeure C, Mateo V, Rubio M, Brown EJ,
Maliszewski C, Lindberg FP, Oldenborg A, Ullrich A, Delespesse
G, Sarfati M (2001) Bidirectional negative regulation of human T
and dendritic cells by CD47 and its cognate receptor signal-
regulator protein-alpha: down-regulation of IL-12 responsiveness
and inhibition of dendritic cell activation. J Immunol
167:2547–2554.
Li Z, Wei H, Piirainen S, Chen Z, Kalso E, Pertovaara A, Tian L (2016)
Spinal versus brain microglial and macrophage activation traits
determine the differential neuroinflammatory responses and
analgesic effect of minocycline in chronic neuropathic pain.
Brain Behav Immun 58:107–117.
Loggia ML, Chonde DB, Akeju O, Arabasz G, Catana C, Edwards
RR, Hill E, Hsu S, Izquierdo-Garcia D, Ji R-R, Riley M, Wasan AD,
Zurcher NR, Albrecht DS, Vangel MG, Rosen BR, Napadow V,
Hooker JM (2015) Evidence for brain glial activation in chronic
pain patients. Brain 138:604–615.
Luo X-G, Chen S-D (2012) The changing phenotype of microglia from
homeostasis to disease. Transl Neurodegener 1:9.
Maegawa H, Morimoto Y, Kudo C, Hanamoto H, Boku A, Sugimura
M, Kato T, Yoshida A, Niwa H (2015) Neural mechanism
underlying hyperalgesic response to orofacial pain in
Parkinson’s disease model rats. Neurosci Res 96:59–68.
Maiaru M, Tochiki KK, Cox MB, Annan LV, Bell CG, Feng X, Hausch
F, Geranton SM (2016) The stress regulator FKBP51 drives
chronic pain by modulating spinal glucocorticoid signaling. Sci
Transl Med 8:325ra19.
Mattioli T-AM, Milne B, Cahill CM (2010) Ultra-low dose naltrexone
attenuates chronic morphine-induced gliosis in rats. Mol Pain
6:22.
Mattioli T-AM, Leduc-Pessah H, Skelhorne-Gross G, Nicol CJB,
Milne B, Trang T, Cahill CM (2014) Toll-Like, Receptor 4 Mutant
and Null Mice Retain Morphine-Induced Tolerance, Hyperalgesia,
and Physical Dependence. PLoS One 9(5):e97361.
Melik Parsadaniantz S, Rivat C, Rostene W, Reaux-Le Goazigo A
(2015) Opioid and chemokine receptor crosstalk: a promising
target for pain therapy? Nat Rev Neurosci 16:69–78.
Melzer P, Zhang MZ, McKanna JA (1997) Infraorbital nerve
transection and whisker follicle removal in adult rats affect
microglia and astrocytes in the trigeminal brainstem. A study
with lipocortin1- and S100beta-immunohistochemistry.
Neuroscience 80:459–472.
Mercadante S (1998) Pathophysiology and treatment of opioid-
related myoclonus in cancer patients. Pain 74:5–9.
Obata H, Eisenach JC, Hussain H, Bynum T, Vincler M (2006) Spinal
glial activation contributes to postoperative mechanical
hypersensitivity in the rat. J Pain 7:816–822.
Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates.
4th ed. San Diego (USA): Academic Press.
Penttinen A-M, Suleymanova I, Albert K, Anttila J, Voutilainen MH,
Airavaara M (2016) Characterization of a new low-dose 6-
hydroxydopamine model of Parkinson’s disease in rat. J
Neurosci Res 94:318–328.
Popiolek-Barczyk K, Kolosowska N, Piotrowska A, Makuch W,
Rojewska E, Jurga AM, Pilat D, Mika J (2015) Parthenolide
relieves pain and promotes M2 microglia/macrophage polarization
in rat model of neuropathy. Neural Plast 2015:676473.
Powell KJ, Ma W, Sutak M, Doods H, Quirion R, Jhamandas K (2000)
Blockade and reversal of spinal morphine tolerance by peptide
and non-peptide calcitonin gene-related peptide receptor
antagonists. Br J Pharmacol 131:875–884.
24 V. Jokinen et al. / Neuroscience 375 (2018) 10–24Raghavendra V, Rutkowski MD, DeLeo JA (2002) The role of spinal
neuroimmune activation in morphine tolerance/hyperalgesia in
neuropathic and sham-operated rats. J Neurosci 22:9980–9989.
Raghavendra V, Tanga F, DeLeo JA (2003) Inhibition of microglial
activation attenuates the development but not existing
hypersensitivity in a rat model of neuropathy. J Pharmacol Exp
Ther 306:624–630.
Ransohoff R (2016) A polarizing question: do M1 and M2 microglia
exist? Nat. Neurosci 19:987–991.
Reddington M, Priller J, Treichel J, Haas C, Kreutzberg GW (1995)
Astrocytes and microglia as potential targets for calcitonin gene
related peptide in the central nervous system. Can J Physiol
Pharmacol 73:1047–1049.
Tang Y, Le W (2016) Differential Roles of M1 and M2 Microglia in
Neurodegenerative Diseases. Mol Neurobiol 53:1181–1194.
Taylor AMW, Castonguay A, Ghogha A, Vayssiere P, Pradhan AAA,
Xue L, Mehrabani S, Wu J, Levitt P, Olmstead MC, De Koninck Y,
Evans CJ, Cahill CM (2016) Neuroimmune regulation of
GABAergic neurons within the ventral tegmental area during
withdrawal from chronic morphine. Neuropsychopharmacology
41:949–959.
Tompkins DA, Campbell CM (2011) Opioid-induced hyperalgesia:
clinically relevant or extraneous research phenomenon? Curr
Pain Headache Rep 15:129–136.
Veinante P, Yalcin I, Barrot M (2013) The amygdala between
sensation and affect: a role in pain. J Mol Psychiatry:1.
Wang Z, Ma W, Chabot J-G, Quirion R (2010) Morphological
evidence for the involvement of microglial p38 activation inCGRP-associated development of morphine antinociceptive
tolerance. Peptides 31:2179–2184.
Watkins LR, Hutchinson MR, Johnston IN, Maier SF (2005) Glia:
novel counter-regulators of opioid analgesia. Trends Neurosci
28:661–669.
Watkins LR, Hutchinson MR, Rice KC, Maier SF (2009) The ‘‘toll” of
opioid-induced glial activation: improving the clinical efficacy of
opioids by targeting glia. Trends Pharmacol Sci 30:581–591.
Zhang R-X, Liu B, Wang L, Ren K, Qiao J-T, Berman BM, Lao L
(2005) Spinal glial activation in a new rat model of bone cancer
pain produced by prostate cancer cell inoculation of the tibia. Pain
118:125–136.
Zhang X-Q, Cui Y, Cui Y, Chen Y, Na X-D, Chen F-Y, Wei X-H, Li Y-
Y, Liu X-G, Xin W-J (2012) Activation of p38 signaling in the
microglia in the nucleus accumbens contributes to the acquisition
and maintenance of morphine-induced conditioned place
preference. Brain Behav Immun 26:318–325.
Zhu J, Qu C, Lu X, Zhang S (2014) Activation of microglia by
histamine and substance P. Cell Physiol Biochem 34:768–780.
Zhuang Z-Y, Wen Y-R, Zhang D-R, Borsello T, Bonny C, Strichartz
GR, Decosterd I, Ji R-R (2006) A peptide c-Jun N-terminal kinase
(JNK) inhibitor blocks mechanical allodynia after spinal nerve
ligation: respective roles of JNK activation in primary sensory
neurons and spinal astrocytes for neuropathic pain development
and maintenance. J Neurosci 26:3551–3560.
Zimmermann M (1983) Ethical guidelines for investigations of
experimental pain in conscious animals. Pain 16:109–110.(Received 29 August 2017, Accepted 23 January 2018)
(Available online 6 February 2018)
